Yazar "Giansily-Blaizot, M." seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Innovative diagnostic tool based on Luminex technology to investigate antibodies directed against FVII(WILEY-BLACKWELL, 2011) Pfeiffer, C.; Lavigne-Lissalde, G.; Tokgoz, H.; Caliskan, U.; Schved, J. F.; Giansily-Blaizot, M.[Abstract not Available]Öğe Successful Prophylactic Use of Recombinant Activated Factor VII (rFVIIa) in a Patient with Congenital FVII Deficiency and Inhibitors to FVII(WILEY, 2012) Tokgöz, H.; Çalışkan, U.; Lavigne-Lissalde, G.; Giansily-Blaizot, M.Congenital factor VII (FVII) deficiency is a rare, autosomal recessive bleeding disorder. The clinical phenotypes range from asymptomatic condition to severe disease characterized by life-threatening bleedings [1]. Optimal replacement therapy for FVII deficiency consists of recombinant activated factor VII (rFVIIa) or plasma derived FVII (pdFVII) concentrates. Although rare, the formation of neutralizing antibodies to FVII is an important concern of replacement therapy in the treatment of FVII deficiency [1]. Herein, we report the clinical progress of a patient with severe FVII deficiency who developed inhibitors against FVII during treatment with rFVIIa.
